march 2010  sold ssi surgical services inc. business ( ssi ) , a surgical service provider , to a privately-owned healthcare company for approximately $ 25 million and realized a gain of $ 2.2 million , net of tax . october 2007  acquired arrow international , inc. , a leading global supplier of catheter-based medical technology products used for vascular access and cardiac care , for approximately $ 2.1 billion . april 2007  acquired substantially all of the assets of hdj company , inc. , providers of engineering and manufacturing services to medical device manufacturers , for approximately $ 25 million . aerospace segment december 2010  sold the actuation business of our subsidiary telair international incorporated , an aftermarket service and support provider for commercial and military aircraft actuators , to transdigm group , incorporated for approximately $ 94 million and realized a gain of $ 51.2 million , net of tax . march 2009  sold our 51 % interest in airfoil technologies international singapore pte . ltd. ( ati singapore ) , which provides engine repair technologies and services primarily for critical components of flight turbines , including fan blades , compressors and airfoils , to ge pacific private limited for approximately $ 300 million in cash and realized a gain of $ 172.7 million , net of tax . 36 november 2007  acquired nordisk aviation products a/s , which develops , manufactures , and services containers and pallets for air cargo , for approximately $ 32 million . june 2007  sold teleflex aerospace manufacturing group ( tamg ) , a precision-machined components business , for approximately $ 134 million in cash and realized a gain of $ 46.3 million , net of tax . commercial segment june 2010  sold rigging products and services business ( heavy lift ) , a supplier of customized heavy-duty wire rope , wire and synthetic rope assemblies , and related rigging hardware products , to houston wire & cable company for approximately $ 50 million and realized a gain of $ 17.0 million , net of tax . august 2009  sold business units that design and manufacture heavy-duty truck and locomotive auxiliary power units , truck and bus climate control systems , and components and systems for the use of alternative fuels in industrial vehicles and passenger cars , to fuel systems solutions , inc. for approximately $ 14.5 million in cash and realized a loss of $ 3.3 million , net of tax . december 2007  divested business units that design and manufacture automotive and industrial driver controls , motion systems and fluid handling systems ( the gms businesses ) , to kongsberg automotive holdings for $ 560 million in cash and realized a gain of $ 93.4 million , net of tax . health care reform on march 23 , 2010 the patient protection and affordable care act was signed into law . while providing some clarity on the impact of reform to our industry , this legislation will nevertheless have a significant impact on our business . for medical device companies such as teleflex , the expansion of medical insurance coverage should lead to greater utilization of the products we manufacture , but this legislation also contains provisions designed to contain the cost of healthcare , which could negatively affect pricing of our products . in addition , commencing in 2013 , the legislation imposes a 2.3 % excise tax on sales of medical devices . as this new law is implemented over the next 2-3 years , we will be in a better position to ascertain its impact on our business . we currently estimate the impact of the medical device excise tax will be approximately $ 16 million annually , beginning in 2013. also in the first quarter of 2010 , we evaluated the change in the tax regulations related to the medicare part d subsidy as currently outlined in the new legislation and determined that it did not have a significant impact on our financial position or results of operations . global economic conditions global recessionary conditions during 2009 and 2008 had adverse impacts on market activities including , among other things , failure of financial institutions , falling asset values , diminished liquidity , and reduced demand for products and services of the past few years . for teleflex , these economic developments principally affected our aerospace and commercial segments and in response , we adjusted production levels and engaged in new restructuring activities in the fourth quarter of 2008 and in the first half of 2009. although , on a consolidated basis , the economic conditions did not have a significant adverse impact on our financial position , results of operations or liquidity during 2010 and 2009 , the continuation of the present broad economic trends of weak economic growth , constricted credit and public sector austerity measures in response to growing public budget deficits could adversely affect our operations in the future , as described below . the potential effect of these factors on our current and future liquidity is discussed below under liquidity and capital resources in this management 's discussion and analysis of financial condition and results of operations. medical  our medical segment serves a diverse base of hospitals and healthcare providers in more than 130 countries . healthcare policies and practice trends vary by country , and the impact of the 37 global economic downturn was felt to varying degrees in each of our regional markets during 2010 and 2009. hospitals in some regions of the united states experienced a decline in admissions , a weaker payor mix , and a reduction in elective procedures . hospitals consequently took actions to reduce their costs , including limiting their capital spending . story_separator_special_tag additional information regarding our segments , including a reconciliation of segment operating profit to income from continuing operations before interest , extinguishments of debt , taxes and minority interest , is presented in note 17 to our consolidated financial statements included in this annual report on form 10-k. medical comparison of 2010 and 2009 medical segment net revenues for 2010 of $ 1,433.3 million were essentially unchanged from the $ 1,434.9 million reported in the same period last year , as core growth of 1 % was offset by the impact of the deconsolidation of a variable interest entity ( 1 % ) . the increase in core revenue was predominantly in the european and asia/latin american critical care product groups and oem specialty sutures and other devices , offset by declines in oem orthopedic implant products and in north american surgical products 43 net revenues for 2010 , 2009 and 2008 by product group for the medical segment are comprised of the following : replace_table_token_21_th ( a ) other in 2009 and 2008 included the net revenues of a variable interest entity that was deconsolidated in the first quarter of 2010 as a result of the adoption of new accounting guidance . see note 2 to our consolidated financial statements included in this annual report on form 10-k for information on the new accounting guidance . critical care critical care revenues in 2010 were negatively impacted approximately $ 17 million when compared to 2009 due to the recall of our custom iv tubing product during the first quarter of 2010 , which contributed to a decline in vascular access sales . this decline was offset by higher sales of other vascular access and urology products in north america and europe , anesthesia products ( in europe , north america and asia/latin america ) and respiratory products in north america and asia/latin america compared with the prior year . surgical care surgical core revenue increased 1 % in 2010 compared to 2009 , primarily due to higher ligation sales in asia/latin america and europe , partially offset by lower sales of general instrument and closure devices in north america . cardiac care sales of cardiac care products in 2010 compared to 2009 were affected positively by higher sales of intra aortic balloon pumps and catheters , primarily in european markets , offset by an approximate $ 3 million impact from the recall of certain intra-aortic balloon catheters during the fourth quarter of 2010. original equipment manufacturers ( oem ) and development services sales of devices to oems increased approximately $ 4.4 million in 2010 compared to 2009. core revenue to oems increased 4 % in 2010 compared with 2009. this increase is largely attributable to higher sales of specialty suture and catheter fabrication products , partially offset by lower sales of orthopedic implant products and forged instruments due to customer inventory rebalancing and a reduction in new product launches by oem customers . medical segment operating profit decreased 9 % in 2010 from $ 302.6 million in 2009 to $ 276.1 million in 2010. operating results for 2010 were negatively impacted by approximately $ 22 million in costs associated with the recall and remediation of our custom iv tubing product and certain intra-aortic balloon catheters and a factory shut down associated with the custom iv tubing product , approximately $ 4 million for other product remediation activities , approximately $ 6 million in higher research and development costs , and approximately $ 16 million in higher costs for sales , marketing , and clinical education programs . these factors more than offset the positive contribution of approximately $ 17 million from higher sales volumes of products not affected by 44 the impact of product recalls , approximately $ 5 million lower manufacturing costs as a result of cost reduction initiatives and approximately $ 4 million lower expenses related to the remediation of fda regulatory issues . comparison of 2009 and 2008 medical segment net revenues declined 3 % in 2009 to $ 1,434.9 million , from $ 1,475.6 million in 2008 , entirely due to foreign currency fluctuations , mainly the stronger u.s. dollar against the euro during the first three quarters of 2009. in the aggregate , we experienced no growth in core revenue in 2009 over 2008 , as growth in critical care products in europe and asia/latin america of approximately $ 11 million was offset by approximately $ 9 million lower sales of orthopedic instrumentation products to oems in north america and approximately $ 8 million lower sales of surgical products in north america and europe . critical care the decrease in critical care product sales during 2009 compared to 2008 was entirely due to currency fluctuations as core revenue in this product group increased approximately 1 % in 2009. higher sales of vascular access , urology and anesthesia products of approximately $ 12 million were partially offset by approximately $ 6 million lower sales of respiratory products , principally as a result of distributor de-stocking in north america in early 2009. surgical care surgical product sales declined approximately 4 % in 2009 compared to 2008. foreign currency movements negatively impacted sales by approximately 3 % , and lower sales in the instrumentation product line in europe and north america led the 1 % decline in core revenue . we believe this decline in sales resulted from hospitals limiting their capital budgets for these products and distributors reducing inventory in the supply chain . cardiac care the decrease in sales of cardiac care products in 2009 compared to 2008 is mainly due to currency movements , hospital capital budget constraints and a voluntary product recall during the first quarter of 2009. oem and development services sales of devices to oems decreased primarily as a result of approximately $ 9 million lower sales of orthopedic instrumentation as higher sales of specialty sutures and other devices of approximately $ 2 million was offset by the impact of currency movements

cash flow from investing activities investing activities from continuing operations provided net cash of $ 148.4 million in 2010 , primarily due to $ 24.7 million in proceeds from the sale of ssi , $ 50.0 million from the sale of heavy lift and $ 93.9 million from the sale of the actuation business , partly offset by capital expenditures of $ 33.5 million . our cash flows from investing activities from continuing operations in 2009 consisted primarily of proceeds from the sales of the ati businesses and power systems operations , partly offset by capital expenditures of $ 28.7 million . cash flow from financing activities financing activities from continuing operations used net cash of $ 336.6 million in 2010. during the third quarter of 2010 , in connection with the refinancing of a portion of our long-term debt , we issued $ 400.0 million in aggregate principal amount of convertible notes . as part of our effort to reduce the potential dilution resulting from the issuance of our common stock and or reduce our exposure to potential cash payments we may be required to make upon conversion of the convertible notes , we entered into hedging transactions involving the purchase of call options and the sale of warrants ( see note 9 to our consolidated financial statements included in this annual report on form 10-k for further information ) . we used approximately $ 88.0 million of the convertible note proceeds to purchase the call options , which was partially offset by the receipt of $ 59.4 million from the sale of the warrants . we used $ 200.0 million of the convertible note proceeds to repay term loan borrowings under our senior credit facility . in connection with the refinancing transactions we incurred $ 21.4 million of transaction fees and expenses , including underwriters ' discounts and commissions .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flow from investing activities investing activities from continuing operations provided net cash of $ 148.4 million in 2010 , primarily due to $ 24.7 million in proceeds from the sale of ssi , $ 50.0 million from the sale of heavy lift and $ 93.9 million from the sale of the actuation business , partly offset by capital expenditures of $ 33.5 million . our cash flows from investing activities from continuing operations in 2009 consisted primarily of proceeds from the sales of the ati businesses and power systems operations , partly offset by capital expenditures of $ 28.7 million . cash flow from financing activities financing activities from continuing operations used net cash of $ 336.6 million in 2010. during the third quarter of 2010 , in connection with the refinancing of a portion of our long-term debt , we issued $ 400.0 million in aggregate principal amount of convertible notes . as part of our effort to reduce the potential dilution resulting from the issuance of our common stock and or reduce our exposure to potential cash payments we may be required to make upon conversion of the convertible notes , we entered into hedging transactions involving the purchase of call options and the sale of warrants ( see note 9 to our consolidated financial statements included in this annual report on form 10-k for further information ) . we used approximately $ 88.0 million of the convertible note proceeds to purchase the call options , which was partially offset by the receipt of $ 59.4 million from the sale of the warrants . we used $ 200.0 million of the convertible note proceeds to repay term loan borrowings under our senior credit facility . in connection with the refinancing transactions we incurred $ 21.4 million of transaction fees and expenses , including underwriters ' discounts and commissions .
```    
 Suspicious Activity Report : march 2010  sold ssi surgical services inc. business ( ssi ) , a surgical service provider , to a privately-owned healthcare company for approximately $ 25 million and realized a gain of $ 2.2 million , net of tax . october 2007  acquired arrow international , inc. , a leading global supplier of catheter-based medical technology products used for vascular access and cardiac care , for approximately $ 2.1 billion . april 2007  acquired substantially all of the assets of hdj company , inc. , providers of engineering and manufacturing services to medical device manufacturers , for approximately $ 25 million . aerospace segment december 2010  sold the actuation business of our subsidiary telair international incorporated , an aftermarket service and support provider for commercial and military aircraft actuators , to transdigm group , incorporated for approximately $ 94 million and realized a gain of $ 51.2 million , net of tax . march 2009  sold our 51 % interest in airfoil technologies international singapore pte . ltd. ( ati singapore ) , which provides engine repair technologies and services primarily for critical components of flight turbines , including fan blades , compressors and airfoils , to ge pacific private limited for approximately $ 300 million in cash and realized a gain of $ 172.7 million , net of tax . 36 november 2007  acquired nordisk aviation products a/s , which develops , manufactures , and services containers and pallets for air cargo , for approximately $ 32 million . june 2007  sold teleflex aerospace manufacturing group ( tamg ) , a precision-machined components business , for approximately $ 134 million in cash and realized a gain of $ 46.3 million , net of tax . commercial segment june 2010  sold rigging products and services business ( heavy lift ) , a supplier of customized heavy-duty wire rope , wire and synthetic rope assemblies , and related rigging hardware products , to houston wire & cable company for approximately $ 50 million and realized a gain of $ 17.0 million , net of tax . august 2009  sold business units that design and manufacture heavy-duty truck and locomotive auxiliary power units , truck and bus climate control systems , and components and systems for the use of alternative fuels in industrial vehicles and passenger cars , to fuel systems solutions , inc. for approximately $ 14.5 million in cash and realized a loss of $ 3.3 million , net of tax . december 2007  divested business units that design and manufacture automotive and industrial driver controls , motion systems and fluid handling systems ( the gms businesses ) , to kongsberg automotive holdings for $ 560 million in cash and realized a gain of $ 93.4 million , net of tax . health care reform on march 23 , 2010 the patient protection and affordable care act was signed into law . while providing some clarity on the impact of reform to our industry , this legislation will nevertheless have a significant impact on our business . for medical device companies such as teleflex , the expansion of medical insurance coverage should lead to greater utilization of the products we manufacture , but this legislation also contains provisions designed to contain the cost of healthcare , which could negatively affect pricing of our products . in addition , commencing in 2013 , the legislation imposes a 2.3 % excise tax on sales of medical devices . as this new law is implemented over the next 2-3 years , we will be in a better position to ascertain its impact on our business . we currently estimate the impact of the medical device excise tax will be approximately $ 16 million annually , beginning in 2013. also in the first quarter of 2010 , we evaluated the change in the tax regulations related to the medicare part d subsidy as currently outlined in the new legislation and determined that it did not have a significant impact on our financial position or results of operations . global economic conditions global recessionary conditions during 2009 and 2008 had adverse impacts on market activities including , among other things , failure of financial institutions , falling asset values , diminished liquidity , and reduced demand for products and services of the past few years . for teleflex , these economic developments principally affected our aerospace and commercial segments and in response , we adjusted production levels and engaged in new restructuring activities in the fourth quarter of 2008 and in the first half of 2009. although , on a consolidated basis , the economic conditions did not have a significant adverse impact on our financial position , results of operations or liquidity during 2010 and 2009 , the continuation of the present broad economic trends of weak economic growth , constricted credit and public sector austerity measures in response to growing public budget deficits could adversely affect our operations in the future , as described below . the potential effect of these factors on our current and future liquidity is discussed below under liquidity and capital resources in this management 's discussion and analysis of financial condition and results of operations. medical  our medical segment serves a diverse base of hospitals and healthcare providers in more than 130 countries . healthcare policies and practice trends vary by country , and the impact of the 37 global economic downturn was felt to varying degrees in each of our regional markets during 2010 and 2009. hospitals in some regions of the united states experienced a decline in admissions , a weaker payor mix , and a reduction in elective procedures . hospitals consequently took actions to reduce their costs , including limiting their capital spending . story_separator_special_tag additional information regarding our segments , including a reconciliation of segment operating profit to income from continuing operations before interest , extinguishments of debt , taxes and minority interest , is presented in note 17 to our consolidated financial statements included in this annual report on form 10-k. medical comparison of 2010 and 2009 medical segment net revenues for 2010 of $ 1,433.3 million were essentially unchanged from the $ 1,434.9 million reported in the same period last year , as core growth of 1 % was offset by the impact of the deconsolidation of a variable interest entity ( 1 % ) . the increase in core revenue was predominantly in the european and asia/latin american critical care product groups and oem specialty sutures and other devices , offset by declines in oem orthopedic implant products and in north american surgical products 43 net revenues for 2010 , 2009 and 2008 by product group for the medical segment are comprised of the following : replace_table_token_21_th ( a ) other in 2009 and 2008 included the net revenues of a variable interest entity that was deconsolidated in the first quarter of 2010 as a result of the adoption of new accounting guidance . see note 2 to our consolidated financial statements included in this annual report on form 10-k for information on the new accounting guidance . critical care critical care revenues in 2010 were negatively impacted approximately $ 17 million when compared to 2009 due to the recall of our custom iv tubing product during the first quarter of 2010 , which contributed to a decline in vascular access sales . this decline was offset by higher sales of other vascular access and urology products in north america and europe , anesthesia products ( in europe , north america and asia/latin america ) and respiratory products in north america and asia/latin america compared with the prior year . surgical care surgical core revenue increased 1 % in 2010 compared to 2009 , primarily due to higher ligation sales in asia/latin america and europe , partially offset by lower sales of general instrument and closure devices in north america . cardiac care sales of cardiac care products in 2010 compared to 2009 were affected positively by higher sales of intra aortic balloon pumps and catheters , primarily in european markets , offset by an approximate $ 3 million impact from the recall of certain intra-aortic balloon catheters during the fourth quarter of 2010. original equipment manufacturers ( oem ) and development services sales of devices to oems increased approximately $ 4.4 million in 2010 compared to 2009. core revenue to oems increased 4 % in 2010 compared with 2009. this increase is largely attributable to higher sales of specialty suture and catheter fabrication products , partially offset by lower sales of orthopedic implant products and forged instruments due to customer inventory rebalancing and a reduction in new product launches by oem customers . medical segment operating profit decreased 9 % in 2010 from $ 302.6 million in 2009 to $ 276.1 million in 2010. operating results for 2010 were negatively impacted by approximately $ 22 million in costs associated with the recall and remediation of our custom iv tubing product and certain intra-aortic balloon catheters and a factory shut down associated with the custom iv tubing product , approximately $ 4 million for other product remediation activities , approximately $ 6 million in higher research and development costs , and approximately $ 16 million in higher costs for sales , marketing , and clinical education programs . these factors more than offset the positive contribution of approximately $ 17 million from higher sales volumes of products not affected by 44 the impact of product recalls , approximately $ 5 million lower manufacturing costs as a result of cost reduction initiatives and approximately $ 4 million lower expenses related to the remediation of fda regulatory issues . comparison of 2009 and 2008 medical segment net revenues declined 3 % in 2009 to $ 1,434.9 million , from $ 1,475.6 million in 2008 , entirely due to foreign currency fluctuations , mainly the stronger u.s. dollar against the euro during the first three quarters of 2009. in the aggregate , we experienced no growth in core revenue in 2009 over 2008 , as growth in critical care products in europe and asia/latin america of approximately $ 11 million was offset by approximately $ 9 million lower sales of orthopedic instrumentation products to oems in north america and approximately $ 8 million lower sales of surgical products in north america and europe . critical care the decrease in critical care product sales during 2009 compared to 2008 was entirely due to currency fluctuations as core revenue in this product group increased approximately 1 % in 2009. higher sales of vascular access , urology and anesthesia products of approximately $ 12 million were partially offset by approximately $ 6 million lower sales of respiratory products , principally as a result of distributor de-stocking in north america in early 2009. surgical care surgical product sales declined approximately 4 % in 2009 compared to 2008. foreign currency movements negatively impacted sales by approximately 3 % , and lower sales in the instrumentation product line in europe and north america led the 1 % decline in core revenue . we believe this decline in sales resulted from hospitals limiting their capital budgets for these products and distributors reducing inventory in the supply chain . cardiac care the decrease in sales of cardiac care products in 2009 compared to 2008 is mainly due to currency movements , hospital capital budget constraints and a voluntary product recall during the first quarter of 2009. oem and development services sales of devices to oems decreased primarily as a result of approximately $ 9 million lower sales of orthopedic instrumentation as higher sales of specialty sutures and other devices of approximately $ 2 million was offset by the impact of currency movements

